SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

March 14, 2013 09:03 ET

Implant Sciences Wins $585,000 Contract for QS-H150 Explosives Trace Detectors to U.S. Government Agency

WILMINGTON, MA--(Marketwire - Mar 14, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has won a contract valued at approximately $585,000 for the sale of its Quantum Sniffer™ QS-H150 explosives trace detectors to a U.S. Government agency. 

"Implant Sciences' products are capable of fulfilling counter-terrorism needs in a wide range of environments," noted Todd Swearingen, General Manager of the Americas for Implant Sciences. "The Company has recently received orders from a number of new U.S. Government customers, and we look forward to more in the coming months as our reputation for reliability, low total cost of ownership, ease of use, and precise detection continues to grow."

Darryl Jones, Implant Sciences' Vice President of Sales and Marketing, commented, "Our investment in sales and marketing infrastructure to serve the U.S. Government market is paying off, and we are now bidding for and winning contracts with U.S. Government agencies. The performance of our products under field conditions continues to open new opportunities with government decision makers. The recent TSA approval of the QS-B220 should only increase these opportunities."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector
The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector
The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact